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Sudden death during follow-up after new-onset
ventricular tachycardia in vascular surgery patients
Tamara A. Winkel, PhD,a Michiel T. Voute, MD,a Mirko de Melis, PhD,b Sanne E. Hoeks, PhD,a Olaf
Schouten, PhD,c Roger Kessels, PhD,b Hence J.M. Verhagen, PhD,a and Don Poldermans,
PhD,a Rotterdam, Maastricht, and Delft, The Netherlands
Background: Vascular surgery patients are at increased risk for late sudden cardiac death. Identification of patients at risk
during surgery offers the opportunity for focused therapy.
Methods: We monitored 483 vascular surgery patients who had no documented history of arrhythmias to identify
perioperative new-onset ventricular tachyarrhythmia (VT) and myocardial ischemia using a continuous electrocardio-
graphic (ECG) device for 72 hours. Cardiac risk factors, left ventricular ejection fraction (LVEF), medical therapy,
inflammation status, and perioperative ischemia in relation to arrhythmia were noted in all patients. During follow-up,
event-based outcomes analysis was used to describe survival.
Results: New-onset perioperative VT was detected in 33 patients (6.8%). A higher percentage of patients experiencing
perioperative VT had reduced LVEF preoperatively than those without VT (24% vs 12%; P  .04). Additionally, fewer
patients experiencing VT were receiving statins than those without (70% vs 85%; P  .02). Patients experiencing VT had
a higher incidence of myocardial ischemia (30% vs 18%; P .10). Perioperative VT was preceded by ischemia in only 60%
of the cases. The overall cohort survival was 83% at 24-month follow-up (interquartile range [IQR], 1.1-1.3). Sudden
cardiac death free survival among patients experiencing VT was less than in those without (79% vs 92%; P  .02). After
adjusting for gender, cardiac risk factors, and type of surgery, new-onset perioperative VT was associated with sudden
cardiac death (hazard ratio [HR], 2.6; 95% confidence interval [CI], 1.1-5.8).
Conclusion: Perioperative VT is likely to be associated with late sudden cardiac death and decreased survival. Continuous
perioperative ECG is an effective method to identify VT and may allow improved management of these patients. ( J Vasc
Surg 2011;53:732-7.)
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oSudden cardiac death is among the most common
causes of death in developed countries. Sudden cardiac
death accounts for more deaths each year, and it is esti-
mated that more than 3 million people die yearly from
sudden cardiac death worldwide.1 The incidence of sudden
cardiac arrest in the general Dutch population is 9.2 per
10,000 inhabitants.2 This can be extrapolated to approxi-
mately 40 sudden cardiac arrests per day in The Nether-
lands.3 In Dutch patients who had undergone 24-hour
ambulatory electrocardiography (ECG) monitoring for
various indications, 3.7% of the patients experienced sud-
den death within 2 years after ECG.4 The majority (80% to
85%) of such sudden cardiac deaths are caused by acute
ventricular tachyarrhythmia (VT), which can be triggered
by acute coronary events, which may occur in persons
without known cardiac disease or in association with struc-
tural heart disease.1,5
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732Patients undergoing vascular surgery are at increased
isk of cardiac events, such as cardiac arrhythmias and
yocardial infarction (MI).6 The use of perioperative
ontinuous-ECG monitoring to screen for the presence of
schemia and arrhythmia increases the number of patients
dentified with arrhythmic events and may help to improve
anagement of patients at risk for subsequent cardiac
vents.7 The significant influence of an increased incidence
nd detection of perioperative myocardial ischemia and
rrhythmias in vascular surgery patients has been described
reviously.8 In this study, we tried to identify vascular
urgery patients at risk of developing new-onset periopera-
ive VT, registered with continuous ECG, and late sudden
ardiac death.
ETHODS
Study population. The prospective study cohort con-
isted of 483 patients undergoing vascular surgery at the
rasmus Medical Center in Rotterdam, The Netherlands,
rom December 2004 to October 2009. Patients with a
istory of cardiac arrhythmias, cardiac pacemaker, and/or
mplantable cardioverter defibrillator (ICD) were ex-
luded. Procedures that precluded continuousHolter ECG
onitoring were excluded. The hospital’s ethical commit-
ee approved this study.
Preoperative cardiac screening. The relationship be-
ween patient characteristics and the risk of adverse cardiac
utcome was determined at the outpatient clinic, as previ-
usly described by Boersma et al.9 We determined the
ardiac risk score for each patient in our dataset, and one
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Volume 53, Number 3 Winkel et al 733point was assigned to each of the following characteristics:
advanced age (70 years), history of MI, angina pectoris
(AP), congestive heart failure (CHF), stroke (transient
ischemic attack, and/or cerebral vascular accident), diabe-
tes mellitus (fasting glucose level 7.0 mmol/L, or use of
insulin, or oral glucose lowering medication), and renal
insufficiency (serum creatinine 170 umol/L).9 Based on
the number of these risk factors, patients were stratified into
low-risk (no risk factors), intermediate-risk (1 or 2 risk
factors), and high-risk (3 risk factors) categories.9 Venous
blood samples for C-reactive protein (CRP), N-terminal
pro-B-type natriuretic peptide (NT-proBNP), low-density
lipoprotein (LDL), and high-density lipoprotein (HDL)
were routinely performed at the outpatient clinic. A preop-
erative ECG assessment of the left ventricle ejection frac-
tion (LVEF) was performed in all patients at the outpatient
clinic. On admission to the hospital, all patients received
beta-blockers.
ECG monitoring. Patients were continuously moni-
tored with a 10-electrode, 12-lead, digital ECG recorder
(DR180 Digital Recorder; NorthEast Monitoring Inc,
Maynard, Mass) for 72 hours perioperatively, starting 1 day
before their surgical procedure and continuing until 2 days
after. ECG data were analyzed for ischemia and new-onset
VTs (sustained ventricular tachycardia and ventricular fi-
brillation [VF]). Sustained ventricular tachycardia was
characterized by three or more consecutive QRS complexes
with a wideQRS complex at a rate of greater than 100 beats
per minute (bpm) and duration greater than 30 seconds.7
VF was defined as chaotic ventricular electrical discharge
with marked variability in QRS cycle length, morphology,
and amplitude.7 Episodes of ischemia were defined as re-
versible ST-segment changes, lasting at least 1 minute and
shifting from baseline by more than 0.1 mV (1 mm). The
baseline ST-segment level was defined as the average ST-
segment value during a stable period of at least 20 mi-
nutes’ duration. The criteria for an ST-depression and
ST-elevation were 0.1 mV flat or down-sloping morphol-
ogy with deviated J-point.10 Standard postoperative 12-
lead ECGs were made on days 3, 7, and 30, and/or at
discharge, and whenever clinically indicated.
Cardiac troponin-T measurement. After surgery,
cardiac troponin-T (cTnT) levels were routinely measured
on postoperative days 1, 3, 7, and 30, and/or before
hospital discharge, and/or whenever clinically indicated by
chest pain complaints or ECG changes consistent with
myocardial ischemia or infarction. The cTnT level was
measured using a whole blood rapid test by an electro-
chemiluminescence immunoassay (TropT version 2; Roche
Diagnostics GmbH, Mannheim, Germany). The lower
limit of cTnT detection was 0.01 ng/mL and the upper
limit of detection was 25 ng/mL, with the limit of quanti-
fication set at 0.03 ng/mL. If cTnT release occurred,
measurements were repeated every day until the level re-
turned to baseline value.
Outcomes. During follow-up, outpatient visits were
scheduled every 3 months after hospital discharge. The
study endpoint was sudden cardiac death. Sudden cardiac neath was defined as a witnessed natural death attributable
o cardiac causes, heralded by abrupt loss of consciousness,
ithin 1 hour of onset of acute symptoms, or an unwit-
essed, unexpected death of someone seen in a stable
edical condition 24 hours previously with no evidence
f a noncardiac cause.11,12 Cardiac death was defined as any
eath with a cardiac cause, including deaths after a cardiac
rocedure, cardiac arrest, MI, pulmonary embolus, stroke,
r sudden death not ascribed to other causes.13 The com-
osite of cardiac death,MI, unstable angina, and stroke was
onsidered as cardiac events. Survival status was determined
y contacting the municipal civil service registry by use of
lectronic medical records and contacting the patient’s
eneral practitioner.
Data analysis. Continuous data are expressed as
ean SD compared using the Student’s t-test. Continu-
us data with a skewed distribution are expressed as medi-
ns with interquartile ranges (IQRs) and were compared
sing the Mann-Whitney U test. Categorical data are de-
cribed as numbers and percentages and analyzed using the
2 test or Fisher’s exact test as appropriate. The relationship
etween new-onset perioperative VT and sudden cardiac
eath was assessed with multivariate Cox regression analy-
is. In multivariate analysis, adjustments were made for
ender, cardiac risk index (medical history of MI, CHF,
troke, AP, renal dysfunction, diabetes, and age) and type
f surgery. In addition, a cumulative 2-year survival curve
or vascular surgery patients experiencing VT and without
erioperative VT was determined by the Kaplan-Meier
ethod and compared using the log-rank test. Odds ratios
nd hazard ratios (HRs) are given with 95% confidence
ntervals (CIs). For all tests, a P value of less than .05
two-sided) was considered significant. All analyses were
erformed using SPSS 15.0 statistical software (SPSS Inc,
hicago, Ill). Continuous ECG recordings and the data
ere analyzed off-line and thus did not influence perioper-
tive treatment management.
ESULTS
Study population. The baseline clinical characteris-
ics and medication use of the 483 included patients under-
oing elective abdominal aortic aneurysm repair (n 241),
eripheral artery bypass surgery (n  101), and carotid
rtery surgery (n 141) are listed in Table I. The mean age
t baseline was 68.6  9.5 years, and 76% were men. The
reoperative cardiac risk was assessed and showed that 18%
ad low risk, 57% had intermediate risk, and 25% had high
isk.
Risk factors for perioperative cardiac arrhythmias.
atients with new-onset VT were significantly older, as
hown in Table I. Twenty-four percent of patients with
erioperative VT had an LVEF lower than 40%, as com-
ared to 12% of those without new-onset VT (P  .04).
atients with perioperative VT had elevated NT-proBNP
evels (36 vs 21 pg/mL; P  .02). A significantly lower
ercentage of patients developing perioperative VT were
reated with statins (70% vs 85%; P  .02), however,
either their baseline inflammation status (preoperative
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March 2011734 Winkel et alCRP 6 vs 4 mg/L), nor LDL (46.8 vs 48.6 mg/dL), or
HDL (23.4 vs 23.4 mg/dL) differed from patients without
perioperative VT. Chronic beta-blocker therapy was used in
88% (388 of 441) of those patients receiving preoperative
beta-blocker therapy.
New-onset perioperative ventricular tachyarrhythmia.
Continuous ECG monitoring started on average 12.4 
7.6 hours before surgery. New-onset perioperative VT
occurred in 33 patients (6.8%), and sustained ventricular
tachycardia and VF occurred in 6.6% and 0.2%, respec-
tively. The vast majority of patients with cardiac arrhyth-
mias (97%) were asymptomatic. All but 1 patient with
new-onset VT returned to sinus rhythm at 30 days postop-
eratively, confirmed by standard 12-lead ECG. As shown in
Table I, significantly more patients undergoing aortic an-
eurysm repair experienced perioperative VT (open, 30% vs
endovascular, 43%), as compared to those undergoing ca-
rotid artery operation (carotid endarterectomy, 6% and
carotid stenting, 3%) and peripheral artery bypass proce-
dure (open, 18%).
VT and myocardial ischemia during continuous
Holter electrocardiogram. Transient myocardial isch-
emia was detected in 93 patients (19.3%), in 9 patients as
ST elevation and 84 patients as ST depression. Patients with
new-onset VT had a higher but nonsignificant incidence of
Table I. Baseline characteristics
No periope
Age, years 6
Males – No. (%) 3
History of myocardial infarction – No. (%) 1
History of angina pectoris – No. (%)
History of congestive heart failure – No. (%)
Diabetes mellitus – No. (%)
Renal dysfunction – No. (%)
History of stroke (TIA and/or CVA) – No. (%) 1
Medication use
-blockers – No. (%) 4
Statins – No. (%) 3
Antiplatelet therapy – No. (%) 3
Oral anticoagulants – No. (%)
Calcium channel blocking agents – No. (%) 1
ACE inhibitors – No. (%) 1
Left ventricular ejection fraction (LVEF)
LVEF 40% – No. (%)
LVEF 40% – No. (%) 3
Laboratory measurements
CRP, mg/L
NT-proBNP, pg/mL
LDL, mmol/L
HDL, mmol/L
Type of surgery
Open AAA repair – No. (%) 1
Endovascular AAA repair – No. (%)
Lower extremity bypass surgery – No. (%)
Carotid endarterectomy – No. (%)
Carotid artery stenting – No. (%)
AAA, Abdominal aortic aneurysm; ACE, angiotensin-converting enzyme; C
LDL, low-density lipoprotein; NT-proBNP, N-terminal pro-B-type natriure
Echocardiographic data (LVEF) were available for 80% of the patients.myocardial ischemia, compared to patients without VT, curing continuous ECG registration (30% vs 18%; P .10,
able II). New-onset perioperative VT was preceded by
yocardial ischemia in 60% of the cases. Patients develop-
ng new-onset VT and myocardial ischemia had signifi-
antly higher postoperative heart rates (median heart rate
0 vs 68; P  .04). Perioperative cTnT release occurred in
5 of 483 patients (16%). In patients experiencing periop-
rative VT, cTnT release occurred nonsignificantly more as
ompared to those not experiencing VT (24% vs 15%,
espectively; P  .15). In addition, cTnT and myocardial
schemia were detected more often in those patients under-
oing elective aneurysm repair (P  .001) as compared to
able II. Events and perioperative VT
No VT
(n  450)
Yes VT
(n  33) P value
yocardial ischemia – No. (%) 83 (18) 10 (30) .10
reoperative heart rate (bpm) 68  12 66  11 .34
ostoperative heart rate (bpm) 73  13 74  12 .65
udden cardiac death – No. (%) 45 (10) 7 (21) .05
ardiovascular events – No. (%) 78 (17) 12 (36) .01
eath – No. (%) 71 (16) 9 (27) .09
pm, Beats per minute; VT, ventricular tachyarrhythmia.
e VT (n  450) Perioperative VT (n  33) P value
9.5 72.1  8.1 .03
76) 29 (88) .11
26) 13 (39) .09
16) 5 (15) .85
6) 5 (15) .06
21) 7 (21) .97
7) 4 (12) .29
38) 6 (18) .02
91) 32 (97) .23
85) 23 (70) .02
78) 24 (73) .52
12) 4 (12) .95
26) 9 (27) .87
27) 10 (30) .71
12) 8 (24) .04
69) 13 (39)
2-9) 6 (3-13) .18
9-50) 36 (15-88) .02
1.0 2.6  0.7 .85
0.4 1.3  0.3 .61
26) 10 (30) .03
22) 14 (43)
21) 6 (18)
21) 2 (6)
10) 1 (3)
-reactive protein; CVA, cerebral vascular; HDL, high-density lipoprotein;
tide; TIA, transient ischemic attack.rativ
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RP, Carotid artery surgery and peripheral bypass procedures.
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Volume 53, Number 3 Winkel et al 735Outcomes. A total of 80 patients (17%) died during
the follow-up period (median follow-up of 2.0 years; IQR,
1.1-3.1), 56 (70%) were due to cardiac causes. Sudden
cardiac death (n  52) occurred in significantly more
patients with perioperative VT compared to those without
VT during vascular surgery (21% vs 10%; P .045, respec-
tively, Table II). The median onset of perioperative VT to
the occurrence of sudden cardiac death was 19 days. As
shown in the Kaplan-Meier curve, the detection of periop-
erative VT was associated with an increased risk of sudden
cardiac death (Fig). In univariate analysis, the development
of new-onset perioperative VT was independently associ-
ated with a significant 2.4-fold increased risk of long-term
sudden cardiac death. After correction for gender, cardiac
risk factors, and type of surgery, new-onset perioperative
VT was still found to be independently associated with
long-term sudden cardiac death and all-cause mortality
(HR, 2.57; 95% CI, 1.14-5.79, respectively, andHR, 2.06;
95% CI, 1.02-4.19, respectively, Table III).
DISCUSSION
The use of perioperative continuous ECG monitoring
to screen for the presence of ischemia and arrhythmia helps
to identify patients at risk for late sudden cardiac death.
More patients with new-onset VT (incidence 6.8%) had a
reduced LVEF and fewer patients received statin therapy
preoperatively. The present study demonstrates that the
identification of new-onset VT in patients undergoing vas-
cular surgery could account for a high proportion of late
sudden cardiac death.
Sudden death from cardiac causes accounts for approx-
imately 50% of all deaths from cardiovascular diseases and
20% of all deaths.2,14,15 In the current study population,
Fig. Kaplan-Meier analysis shows the survival of patients with
new-onset perioperative ventricular tachyarrhythmia (VT) com-
pared to those not experiencing VT at a median follow-up of 24
months (interquartile range [IQR], 1.1-3.1).the incidence of sudden cardiac death was 10.8% (52 of l83). When looking into the patients with perioperative
T, this incidence of sudden cardiac death was higher
21%). The diagnosis of sudden cardiac death is a difficult
xercise, and within a clinical trial, it generally relies on
ource documentation that indicates that death was sudden
nd unexpected, which was the case in the current study.
ecause a large proportion of sudden cardiac death victims
ave no warning symptoms, it would be essential to identify
he patients at high risk of long-term sudden death. In a
tudy by Pouleur et al,16 the specific cause of sudden death
rom autopsy reports was examined and found that 51.4%
f the sudden death cases had no acute specific structural
utopsy evidence and presumed arrhythmia. Despite de-
ades of investigation, the ability to stratify the risk for
udden cardiac death is imperfect at best, as evidenced by
he fact that, even among patients with no risk factors,
udden death occurs at a rate just less than 1% per year;
atients with 3 risk factors seem to have event rates that
pproach 5% per year, whereas even survivors of prior
udden death have a rate of subsequent sudden death of
pproximately 10% per year.17 In the latter, mentioned
tudy by Maron et al,17 the risk factors for sudden death
ere assessed in 506 patients with hypertrophic cardiomy-
pathy and implanted with an ICD. Their conclusion was
hat ICD interventions for life-threatening VTs were fre-
uent and highly effective in restoring normal rhythm and
hat a single marker of high risk for sudden death may be
ufficient to justify consideration for prophylactic defibril-
ator implantation.17 In the current study, sudden cardiac
eath was found more frequently in patients with increased
ardiac risk factors (medical history of MI, AP, stroke,
HF, diabetes, renal dysfunction, and age higher than 70
ears) eg, patients with a high risk had an HR of 2.82 for
udden cardiac death and could thus be indicated for
rophylactic ICD. In the most recently published random-
zed controlled trial by Steinbeck et al,18 however, patients
ith an acute MI had no improved survival after prophy-
actic ICD placement, compared to those treated medically
nly. The main difference between Steinbeck’s study pop-
lation and that from the current study is the fact that all
teinbeck’s patients had an acute MI before being random-
zed to an ICD. In previously published studies19-21 report-
ng that the use of ICD reduces mortality in high-risk
opulations with ischemic disease, patients were recruited
ore than 1 year after the index MI. Hohnloser et al22
onducted the DINAMIT (Defibrillator IN acute MI
rial) and concluded that prophylactic ICD therapy did not
educe overall mortality in high-risk patients with a recent
I (enrolled 6 to 40 days after an acute MI), even though
t was associated with a reduction in the rate of death due to
rrhythmia that was offset by an increase in the rate of death
ue to nonarrhythmic causes.22 In the current study pop-
lation, the majority of patients were treated optimally with
edical therapy. However, it is notable that a lower per-
entage of patients who experienced VT were receiving
reoperative statin therapy (70%) compared to those who
id not experience arrhythmias (85%), even though base-
ine CRP levels were not different between these groups. A
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patients with an ICD were associated with fewer VT/VF
episodes and a 28% reduction in risk of a first VT/VF
episode. It could be hypothesized that the patients devel-
oping perioperative new-onset VT in the current study
could benefit from statin use and that some of the patients,
especially those with VT before MI, may benefit from an
ICD implant to prevent sudden cardiac death. In the end,
the choice whether to pursue an ICD comes down to
whether the individual patients and their physicians per-
ceive that the risk of sudden death outweighs the risk of
device placement. In the current study population, 45 of 52
patients who died due to sudden cardiac death were not
identified with perioperative VT. By extending the ECG
monitoring period with an implantable monitoring device
recording online, the chances of capturing more episodes
of new-onset VT increase, especially those presenting out-
side the 72-hour ECG window, which in turn could en-
hance detection of those at highest risk of sudden death.
Study limitations. Larger studies will make a better
understanding of the triggers for ventricular arrhythmias
and better risk stratification algorithms. This study has the
major limitation that it is a relatively small cohort, which
likely precludes a full characterization of the relationship
between perioperative ventricular arrhythmias and sudden
cardiac death.
In conclusion, perioperative VT during vascular sur-
gery procedures is suggested to be associated with late
sudden cardiac death and decreased survival. Larger studies
will need to be conducted to prove this finding. Long-term
continuous perioperative ECG is an effective method to
identify perioperative VT andmay allow improvedmanage-
ment of patients undergoing vascular operations.
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Dr Richard P. Cambria (Boston, Mass). Congratulations,
your group has been a leader in the entire area of cardiac risk
stratification and events, and it’s a pleasure to comment on a paper
that reinforces one’s personal bias and calls back to the days when
Charlie Boucher and Kim Eagle identified a history of ventricular
arrhythmias as one of the clinical markers.
My question is: Having identified perioperative VT, was phar-
macologic antiarrhythmia therapy instituted in these patients
and/or is that your current recommendation? You mentioned in
the abstract that you might consider an ICD placement in that
circumstance, but how about drug therapy?
Dr Tamara A.Winkel.Unfortunately, we analyze our Holter
data off-line, so only in the cases of clinical signs of dyspnea or
anything that the patient complained of, or with abnormalities on
an electrocardiogram, we could see if there was VT and act on these
findings with medical therapy. So there was no direct pharmaco-
logical implications on these measurements if it was not seen in the
clinical setting or on standard ECG.
However, if we did find and measure or detect these in the
clinical setting itself, then indeed we did use pharmacological
therapies such as beta blockers, in the cases when the patient wasn’t
receiving it or we changed the doses hereof. Also, the patient
received antiplatelet or anticoagulant therapy or statin therapy
when necessary.
And while our data now state that there is a non-significant
difference of ischemia with the patients of ventricular tachycardia,
so we don’t have hard data or arguments to imply an ICD, we do
hope that by enlarging our study population we could say some-
thing more about this ICD implantation in the future. An online
monitoring of the continuous electrocardiogram would be better
and then we can, indeed, imply therapeutic consequences.
Dr Richard P. Cambria. So if we, as practitioners, identify
perioperative VT, what is the appropriate posture? Should antiar-
rhythmic therapy be instituted?
Dr Tamara A. Winkel. Well, with regard to antiarrhythmic
therapy, several studies have been done, and the preference goes
out to beta blockers and antiplatelet or anticoagulation therapy in
cases of ventricular tachycardia. In this study, antiarrhythmic med-Dr Richard P. Cambria. I hate to pin you down, but 98% of
our patients were already on beta blockers.
Dr Tamara A. Winkel. Yes, this is true.
Dr Richard P. Cambria. So that would appear to be insuffi-
ient.
Dr Tamara A.Winkel. You could adjust or change the doses,
ake it a higher dose.
Dr Jack L. Cronenwett (Lebanon, NH). I would also con-
ratulate you on presenting what I think is a novel observation
bout our patients.
My question relates to whether this is a marker for a future
arlier death or does it have a causative relationship? I didn’t
nderstand from your presentation how you were able to classify
udden cardiac deaths. Were you able to analyze the cause of death
n these patients to understand if, in fact, these late deaths that were
ore frequent were related potentially to a ventricular arrhythmia
r is this just a marker for patients, because of their cardiac burden,
ho are going to die earlier? I think that has important implications
or how we might manage them, reply Dr Cambria’s questions,
hen we see them in the hospital.
Dr Tamara A. Winkel. Indeed, it is so that patients with
tructural heart disease or more cardiac risk factors are more prone
o develop these ventricular tachycardia’s. That’s one side of the
roblem.
On the other hand, we do believe that it is an independent
actor for the eventual development of sudden cardiac death. So we
o think that it is an independent marker, but there is also the risk
actors causing them to develop ventricular tachycardia. It’s the
hicken-or-the-egg story, but you can’t really say if ventricular
achycardia’s are either the chicken or the egg in this story. It’s
ifficult. We have shown that it is an independent factor, but we do
elieve that there are other factors contributing to its develop-
ent.
And with regard to your question about sudden cardiac death,
e contacted the general practitioners when the patients were
ischarged. We looked into the survival status with use of the civil
ervice registry data, and contacted the patients via regular visits at
he outpatient clinic. So we really looked into that to the best of
ur abilities, yes.
